{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-020042","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.725707+00:00","generated_at":"2026-05-18T06:01:56.771196+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telomir-1 reverses STAT1 epigenetic silencing in prostate cancer, outperforming Paclitaxel and Rapamycin","bullets":["In PC3 xenograft model, Telomir-1 fully reversed STAT1 hypermethylation after 21-day oral daily dosing.","No STAT1 reversal was seen with Paclitaxel; only partial demethylation was observed with Rapamycin.","Telomir-1 also reduced TMS1 hypermethylation, a pro-apoptotic tumor suppressor involved in immune signaling.","Telomere length in tumor tissue was not elongated, addressing a key safety concern for telomere-targeting compounds.","Company is advancing Telomir-1 toward IND filing and evaluating it in Wilson's disease, AMD, autism, and dysphonia."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-020042","json":"https://secwatch.observer/filing/0001641172-25-020042.json","markdown":"https://secwatch.observer/filing/0001641172-25-020042.md","text":"https://secwatch.observer/filing/0001641172-25-020042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225020042/0001641172-25-020042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225020042/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:01:56.771196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}